Homo sapiens whole clinical trials
How each study uses homo sapiens whole is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the homo sapiens whole studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Sept 2016 · Cuvitru · BLA 125596 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 10
CSL Behring (7) · Baxalta now part of Shire (3) · Grifols Therapeutics LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ADMA Biologics, Inc. (2) · Nabi Biopharmaceuticals (2) · Nycomed (2) · Oregon Health and Science University (1)
Often tested with
Tested in the same studies.
Prothrombin complex concentrate (2) · Immunoglobulins, Intravenous (1) · Immunoglobulin G (1) · Hyaluronidase (human recombinant) (1) · Factor VIII (1) · Zidovudine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test homo sapiens whole, phase 3 first.
Studies
Open first, then newest update. How each study uses homo sapiens whole is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingPhase 3CSL BehringNCT06617897Written as CSL511 Fibrinogen concentrate (human)How we know
- IVIG for Infection Prevention After CAR-T-Cell TherapyRecruitingPhase 2Fred Hutchinson Cancer CenterNCT05952804Written as Immune Globulin Infusion (Human), 10% SolutionHow we know
- Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)RecruitingPhase 4Camille N. Kotton, MDNCT06958796Written as Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three monthsHow we know
- Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for PreventionRecruitingPhase 2Rochester General HospitalNCT05764993Written as CUVITRU - Ig subcutaneous human 20%How we know
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedPhase 1/2Grifols Therapeutics LLCNCT04722887Written as Liquid Alpha1-Proteinase Inhibitor (Human)How we know
- Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac SurgeryTerminatedPhase 4SHI JiaNCT04244981Written as Prothrombin Complex Concentrate, HumanHow we know
- Prehospital Kcentra for Hemorrhagic ShockActive, not recruitingPhase 2Oregon Health and Science UniversityNCT04019015Written as Prothrombin Complex Concentrate, HumanHow we know
- Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve RepairCompletedPhase 3Axogen CorporationNCT01809002Written as Processed Nerve Allograft (human)How we know
- Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedPhase 2Grifols Therapeutics LLCNCT04547140Written as Liquid Alpha1-Proteinase Inhibitor (Human)How we know
- Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.Status unknownPhase 4Antoni Sabaté PesNCT04405518Written as Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]How we know
- A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected ChildrenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000827Written as Anti-HIV Immune Serum Globulin (Human)How we know
- The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001105Written as F105 Monoclonal Antibody (Human)How we know
- Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)CompletedPhase 3ADMA Biologics, Inc.NCT00538915Written as Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]How we know
- Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver TransplantationTerminatedPhase 2ADMA Biologics, Inc.NCT00473824Written as Hepatitis C Immune Globulin Intravenous (Human) 5%How we know
- Phase 2/3 Study of IGSC, 20% in PIDDCompletedPhase 2/3Baxalta now part of ShireNCT01218438Written as Immune Globulin Subcutaneous (Human), 20% SolutionHow we know
- Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaCompletedPhase 3ShireNCT02584959Written as C1 esterase inhibitor [human] liquidHow we know
- Tolerability and Safety of IGI, 10% With rHuPH20 in PIDDCompletedPhase 2/3Baxalta now part of ShireNCT01485796Written as Immune Globulin Infusion (Human), 10%How we know
- Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C DeficiencyCompletedPhase 2/3Baxalta now part of ShireNCT00157118Written as Protein C Concentrate (Human) Vapor HeatedHow we know
- Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.CompletedPhase 4CSL BehringNCT00670007Written as Alpha1- proteinase inhibitor [human]How we know
- CSL Behring Sclero XIIIStatus unknownPhase 2University College, LondonNCT02551042Written as Fibrogammin®P, coagulation factor XIII concentrate (Human)How we know
See all 33 studies that test homo sapiens whole →
Given beside what is tested · 2 — homo sapiens whole is usual care or a partner of the new treatment
- Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.CompletedPhase 1/2Banc de Sang i TeixitsNCT03780894Written as Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]How we know
- Immune Globulin Subcutaenous (Human), 20%CompletedPhase 2/3Baxalta now part of ShireNCT01412385Written as Immune Globulin Subcutaneous (Human), 20%How we know